Protein expression of myc-PDHK4 was also confirmed by western blot analysis of xenograft extracts 22 days post-implant and pull-down assays also showed an increase in KRAS activity in the PDHK4 stable xenograft compared to the control tumours (Figure 7b). This evidence concerns the gene KRAS and neoplasm.